Literature DB >> 12877579

Identification of "latent hits" in compound screening collections.

Jordi Mestres1, Gerrit H Veeneman.   

Abstract

The relatively low hit rates found from high-throughput screening have raised a question on whether this technology alone is sufficient to maximally exploit the full potential of current corporate screening collections. The present study introduces a knowledge-based strategy for identifying "latent hits", i.e., inactive compounds that could potentially be promoted to hits through simple chemical transformations. Examples are given of submicromolar agonist hits derived from the corresponding latent hits for the estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877579     DOI: 10.1021/jm034078c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Advances in Nuclear Magnetic Resonance for Drug Discovery.

Authors:  Robert Powers
Journal:  Expert Opin Drug Discov       Date:  2009-10-01       Impact factor: 6.098

Review 2.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

3.  Targeting metalloproteins by fragment-based lead discovery.

Authors:  Sherida Johnson; Elisa Barile; Biancamaria Farina; Angela Purves; Jun Wei; Li-Hsing Chen; Sergey Shiryaev; Ziming Zhang; Irina Rodionova; Arpita Agrawal; Seth M Cohen; Andrei Osterman; Alex Strongin; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2011-06-16       Impact factor: 2.817

4.  Exploring the ligand-protein networks in traditional chinese medicine: current databases, methods and applications.

Authors:  Mingzhu Zhao; Dongqing Wei
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 5.  Inside job: ligand-receptor pharmacology beneath the plasma membrane.

Authors:  Joseph J Babcock; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.